FDA Approval And NHS Studies Will Transform Cancer Detection
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
15 Jun 25
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$40.50
19.9% undervalued intrinsic discount14 Aug
US$32.43
1Y
93.6%7D
-1.2%